Hormone Replacement Therapy and Coronary Heart Disease: Results of Randomized Trials

Progress in Cardiovascular Diseases

Volumn 46, Issue 3, 2003, Pages 231-238

  Petitti, Diana ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

ATHEROSCLEROSIS; DOSE RESPONSE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; RECURRENT DISEASE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; TREATMENT PLANNING;

EID: 0348140734     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2003.08.002     Document Type: Article

References (48)

1. Hulley S, Grady D, Bush T, et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605-613, 1998
2. Herrington DM, Reboussin DM, Brosnihan KB, et al: Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343: 522-529, 2000
3. Angerer P, Stork S, Kothny W, et al: Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: A randomized, controlled trial. Arterioscler Thromb Vasc Biol 21:262-268, 2001
4. Hodis HN, Mack WJ, Lobo RA, et al: Estrogen in the prevention of atherosclerosis: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135: 939-953, 2001
5. Cherry N, Gilmour K, Hannaford P, et al: Oestrogen therapy for prevention of reinfarction in postmenopausal women: A randomised placebo controlled trial. Lancet 360:2001-2008, 2002
6. Byington RP, Furberg CD, Herrington DM, et al: Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol 22:1692-1697, 2002
7. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
8. Waters DD, Alderman EL, Hsia J, et al: Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: A randomized controlled trial. JAMA 288:2432-2440, 2002
9. Clarke SC, Kelleher J, Lloyd-Jones H, et al: A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: The Papworth HRT atherosclerosis study. BJOG 109:1056-1062, 2002
10. Grady D, Herrington D, BittnerV, et al: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49-57, 2002
11. Hemminki E, McPherson K: Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials. BMJ 315:149-153, 1997
12. Eaker ED, Chesebro JH, Sacks FM, et al: Cardiovascular disease in women. Circulation 88:1999-2009, 1993
13. Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 20:47-63, 1991
14. The Coronary Drug Project: Initial findings leading to modifications of its research protocol. JAMA 214: 1303-1313, 1970
15. The Coronary Drug Project: Findings leading to discontinuation of the 2.5-mg day estrogen group. JAMA 226:652-657, 1973
16. Matthews KA, Kuller LH, Wing RR, et al: Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 143:971-978, 1996
17. Barrett-Connor E: Postmenopausal estrogen and prevention bias. Ann Intern Med 115:455-456, 1991
18. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 303:1038-1041, 1980
19. Horwitz RI, Viscoli CM, Berkman L, et al: Treatment adherence and risk of death after a myocardial infarction. Lancet 336:542-545, 1990
20. Petitti DB: Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies? Ann Epidemiol 4:115-118, 1994
21. Kaplan GA, Keil JE: Socioeconomic factors and cardiovascular disease: A review of the literature. Circulation 88:1993-1998, 1973
22. Humphrey LL, Chan BK, Sox HC: Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 137:273-284, 2002
23. Pfeffer RI, Whipple GH, Kurosaki TT, et al: Coronary risk and estrogen use in postmenopausal women. Am J Epidemiol 107:479-497, 1978
24. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al: Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 54:74-79, 1979
25. Hernandez AM, Walker AM, Jick H: Use of replacement estrogens and the risk of myocardial infarction. Epidemiology 1:128-133, 1990
26. Mann RD, Lis Y, Chukwujindu J, et al: A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women. J Clin Epidemiol 47:307-312, 1994
27. Heckbert SR, Weiss NS, Koepsell TD, et al: Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch Intern Med 157:1330-1336, 1997
28. Varas-Lorenzo C, Garcia-Rodriguez LA, Perez-Gutthann S, et al: Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation 101:2572-2578, 2000
29. Grodstein F, Manson JE, Colditz GA, et al: A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133:933-941, 2000
30. Rosenberg L, Palmer JR, Shapiro S: A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol 137:54-63, 1993
31. Sidney S, Petitti DB, Quesenberry CP Jr: Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med 127:501-508, 1997
32. Sourander L, Rajala T, Raiha I, et al: Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 352:1965-1969, 1988
33. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273:199-208, 1995
34. Nabulsi AA, Folsom AR, White A, et al: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 328:1069-1075, 1993
35. Koh KK, Mincemoyer R, Bui MN, et al: Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 336:683-690, 1997
36. Espeland MA, Hogan PE, Fineberg SE, et al: Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 21:1589-1595, 1998
37. Manolio TA, Furberg CD, Shemanski L, et al: Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation 88:2163-2171, 1993
38. Caine YG, Bauer KA, Barzegar S, et al: Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 68:392-395, 1992
39. Barnabei VM, Phillips TM, Hsia J: Plasma homocysteine in women taking hormone replacement therapy: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Womens Health Gend Based Med 8:1167-1172, 1999
40. Cushman M, Legault C, Barrett-Connor E, et al: Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100: 717-722, 1999
41. Grodstein F, Clarkson TB, Manson JE: Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 348:645-650, 2003
42. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al: Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: a randomized trial. JAMA 289:2673-2684, 2003
43. Shumaker SA, Legault C, Thal L, et al: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 289:2651-2662, 2003
44. Simon JA, Hsia J, Cauley JA, et al: Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 103:638-642, 2001
45. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 282:2340-2346, 1999
46. Lauer MS: Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med 346:1468-1474, 2002
47. Teo KK, Yusuf S, Furberg CD: Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 270:1589-1595, 1993
48. Yusuf S, Sleight P, Pogue J, et al: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000